Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.
Angie Maynard, PharmD, MS, BCOP
Advertisement
Angie Maynard, PharmD, MS, BCOP, is an assistant professor at Lipscomb University.
Articles by Angie Maynard, PharmD, MS, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Health System Pharmacies Keep Patients on GLP-1 Therapy
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5